FDA Approves Moderna's New Lower-Dose COVID-19 Vaccine
The FDA has approved Moderna’s new lower-dose COVID-19 vaccine, mNexspike, offering tailored protection for high-risk populations. Learn more about this innovative development in COVID-19 immunization.
The U.S. Food and Drug Administration (FDA) has officially authorized a new, lower-dose version of Moderna's COVID-19 vaccine, designed to enhance protection in high-risk populations. This innovative vaccine, known as mNexspike, is a significant advancement in coronavirus immunization technology. It features a dose that is approximately one-fifth of the standard amount used in Moderna's Spikevax, achieved through a targeted design that aims to provoke a more focused immune response. Importantly, this new vaccine is not intended to replace the existing Moderna COVID-19 shot but rather to serve as an additional option.
mNexspike is approved specifically for individuals aged 65 and older who have been previously vaccinated with any COVID-19 vaccine, as well as for those aged 12 to 64 who possess at least one underlying health condition that increases their risk of severe illness from COVID-19. This limited authorization aligns with the approval of other targeted vaccines like Novavax's last month.
In the upcoming fall, Moderna plans to offer both Spikevax and mNexspike, providing flexibility in COVID-19 vaccination strategies. The current primary vaccine remains widely accessible for individuals aged 6 months and older without restrictions.
Moderna’s CEO, Stephane Bancel, emphasized that the new lower-dose vaccine is a valuable addition to the arsenal of tools available to protect high-risk groups against severe COVID-19 outcomes. The approval marks an important step in refining vaccine strategies to better address the ongoing pandemic.
For more details, visit source.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Revolutionary Use of E.coli Bacteria Turns Plastic Waste Into Potential Painkillers
Scientists have engineered E. coli bacteria to convert plastic waste into valuable painkillers like paracetamol, offering a potential innovative solution to plastic pollution and pharmaceutical production challenges.
Breakthrough Algorithm Enhances Imaging of Cardiac Tissue and Vessels
A new algorithm improves imaging of cardiac tissue and vessels, enabling earlier diagnosis and better management of cardiovascular diseases by enabling clearer visualization through existing microscopes.
Revolutionizing Transplant Diagnostics with AI-Driven Virtual Tissue Staining
A novel AI-based virtual staining technique enhances transplant biopsy analysis by providing rapid, cost-effective, and reliable tissue diagnostics, improving outcomes for transplant patients.
Pediatricians' Group Recommends COVID-19 Vaccines for Young Children, Diverging from CDC Guidelines
The American Academy of Pediatrics has issued new COVID-19 vaccine recommendations for children, diverging from CDC guidance. The new guidelines advocate for broader vaccination coverage, especially for high-risk kids, amid rising cases and policy shifts, emphasizing individual choice and updated safety data.